Augustine Asset Management Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 51,158 shares of the biopharmaceutical company’s stock, valued at approximately $4,144,000. Gilead Sciences comprises about 2.6% of Augustine Asset Management Inc.’s holdings, making the stock its 12th biggest holding.
Several other large investors also recently made changes to their positions in the company. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences in the second quarter worth about $147,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV bought a new stake in shares of Gilead Sciences in the second quarter worth about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in Gilead Sciences during the 2nd quarter valued at approximately $172,000. 75.94% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.04 during mid-day trading on Friday, reaching $79.02. 6,366,180 shares of the company’s stock were exchanged, compared to its average volume of 8,150,000. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market cap of $103,190.00, a P/E ratio of 8.99, a P/E/G ratio of -1.58 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
The business also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.63%. Gilead Sciences’s dividend payout ratio is currently 23.66%.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 461,666 shares of company stock worth $34,072,567 over the last 90 days. Insiders own 1.30% of the company’s stock.
Several analysts have weighed in on the company. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.03.
COPYRIGHT VIOLATION WARNING: “Augustine Asset Management Inc. Invests $4.14 Million in Gilead Sciences, Inc. (NASDAQ:GILD) Stock” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/12/augustine-asset-management-inc-takes-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.